explore -WSS

explore

author：hotspot 2025-09-30 01:03:06 - browse：4

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

focus

WSS

'Essentially witchcraft:' A former naturopath takes on the field

J&J to emphasize cancer drugs, stop much of its vaccine research

Flagship Pioneering launches a new biotech in two countries

My daughter's legacy lives on through her writing, phage therapy

How faith leaders like me can help address America's obesity epidemic

Mayo Clinic plans $5B tech

knowledge

explore

leisure time

In Memoriam: Notable people who died in 2023

FDA investigates CAR

At least 13 dead in Texas as scorching temps continue

How faith leaders like me can help address America's obesity epidemic

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cigna wins case to block Amy Bricker's move to CVS

Duchenne breakthrough therapy leaves behind pioneering families

Cigna wins case to block Amy Bricker's move to CVS

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readers discuss the intersection of pregnancy and addiction

focus

FDA investigates CAR

Organ aging and disease risk measured by new blood test

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Teladoc has a new CEO, but challenges remain the same

Study: Why relieving medical debt did not improve financial outcomes

NIH tests clinical research in primary care with $30 million program

hotspot

knowledge

focus

explore